Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Fiche publication
Date publication
février 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique, Mme TRUNTZER Caroline, Dr FUMET Jean-David
Tous les auteurs :
Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A
Lien Pubmed
Résumé
Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) patients receiving primary debulking surgery followed by carboplatin-paclitaxel chemotherapy +/- nintedanib.
Mots clés
HLA-E, HRD, copy number alterations, homologous recombination deficiency, ovarian cancer, tumor immune microenvironment
Référence
Cancers (Basel). 2022 Feb 25;14(5):